Working… Menu

Understanding Drug Abuse Treatment Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01678833
Recruitment Status : Completed
First Posted : September 5, 2012
Last Update Posted : April 5, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Drug Abuse (NIDA) )

Brief Summary:


Although some treatments for substance abuse are considered effective for some people who are drug dependent, many others do not benefit as much over time. Researchers are working to find out what characteristics predict treatment response. They also want to determine how to design treatments that are more effective for a greater number of substance abusers. This pilot study involves providing drug addicts with cognitive behavioral therapy (CBT), a treatment considered to be one of the most effective in reducing substance-abuse, to identify ways in which the brain works that may predict and explain treatment effects. A comparison group will be included that receives only standard psychotherapy or talk therapy. This approach will enable researchers to determine what factors might be interfering with favorable treatment outcomes and how to refine or develop new treatments that work well for more people.


- To identify individual characteristics which predict and explain the effects of CBT in people with opiate dependence.


  • Males between 18 and 60 years of age who are dependent on opioids (such as heroin).
  • Participants must be willing to take buprenorphine and receive substance abuse counseling.


  • Participants will be screened with a physical exam and medical history.
  • Researchers will ask questions about participants ability to cope in certain situations, along with questions about drug use and lifestyle issues. These questions will be asked twice, before and after completing treatment.
  • Participants will be placed into one of two groups. One group will have CBT twice a week for 8 weeks. The other group will have standard counseling twice per week. Both groups will take buprenorphine as part of the drug abuse treatment.
  • Participants will have other tests during this study. They will have imaging studies to look at brain function. These studies will test thinking and decision making.

Condition or disease
Drug Abuse/Dependence

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 7 participants
Time Perspective: Other
Official Title: Neural Mechanistic Explanations for Differential Drug Abuse Treatment Outcomes
Study Start Date : July 19, 2012
Study Completion Date : March 7, 2016

Primary Outcome Measures :
  1. The focus of our outcome evaluation will be use of opioid (e.g., frequency, days of continuous abstinence, etc.), coping strategies, and change in lifestyle measures (e.g., employment, relationships, behavioral problems, treatment engagement).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Participants will be eligible for inclusion in the study if they meet the following criteria:

  1. Right-handed individuals between the ages of 18 and 60;
  2. Good physical condition;
  3. Participating and receiving buprenorphine treatment in protocol 09-DA-N020, a study being conducted in the NIDA Intramural Archway Clinic (Dr. Kenzie Preston, PI) in Baltimore, MD OR at outpatient treatment facilities at UMMC (ADAP or OATS);
  4. Heroin or other opioid dependent;
  5. Suitable for MRI scanning;


Participants will be excluded from this study if they:

  1. History of neurological illnesses including but not limited to CVA, CNS tumor, head trauma, MS or other demyelinating diseases, epilepsy, movement disorders, or migraine in treatment.
  2. Are HIV infected.
  3. Have deep vein thrombosis (DVT): Assessment tool: self report during H&P of thrombosis, family history of thrombosis, or a medical condition that may lead to a hypercoagulable state Rationale: Lying still for an hour (plus the mock scanning session) may be a risk for the development of DVT in persons with certain medical conditions. As such, persons with will be excluded.
  4. Have current suicidal ideation.
  5. Are unable to undergo MRI scanning due to metallic devices in the body including dental braces, claustrophobia or body morphometry.
  6. Are currently using respiratory, cardiovascular or anticonvulsant medications that may interfere with the BOLD MRI signal.
  7. Cognitively impaired;
  8. Continued noncompliance (after the 3rd time) with respect to testing positive for illicit drugs or reporting caffeine use in the past 12 hours or alcohol use in the past 24 hours when they visit for their scanning sessions will lead to discontinuing their participation in the #480 protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01678833

Layout table for location information
United States, Maryland
National Institute on Drug Abuse
Baltimore, Maryland, United States, 21224
University of Maryland
Baltimore, Maryland, United States
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Elliot Stein, Ph.D. National Institute on Drug Abuse (NIDA)
Layout table for additonal information
Responsible Party: National Institute on Drug Abuse (NIDA) Identifier: NCT01678833    
Other Study ID Numbers: 999912480
First Posted: September 5, 2012    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: March 7, 2016
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Drug Abuse (NIDA) ):
Drug Abuse/Dependence
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders